Deutsche Bank upgraded Alcon from Hold to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2026 | $97.00 | Equal Weight → Overweight | Wells Fargo |
| 1/30/2026 | Mkt Perform | William Blair | |
| 1/20/2026 | Hold → Buy | Deutsche Bank | |
| 1/9/2026 | Buy → Hold | Stifel | |
| 12/11/2025 | $75.00 | Buy → Underperform | BofA Securities |
| 8/21/2025 | Overweight → Neutral | Analyst | |
| 5/20/2025 | Buy → Hold | Deutsche Bank | |
| 5/14/2025 | $102.00 → $99.00 | Buy | BTIG Research |
First-quarter 2026 sales of $2.7 billion, up 10% on a reported basis, or up 6% constant currency1 (cc), versus first-quarter 2025 First-quarter 2026 diluted EPS of $0.39; core diluted EPS2 of $0.85 Dividend of 0.28 CHF per share approved at AGM Announced new $1.5 billion share repurchase authorization over 3 years Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31, 2026. For the first quarter of 2026, sales were $2.7 billion, up 10% on a reported basis and up 6% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported dilu
Shareholders approve all agenda items presented R. Scott Herren elected as new independent member of the Board 2025 Compensation Report and Report on Non-Financial Matters approved in consultative votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2026 Annual General Meeting ("AGM"). A total of 283,222,421 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 11,328,896.84, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the
New partnership raises awareness of dry eye, a condition affecting an estimated 8.5 million Canadians1, helping fans stay comfortable throughout the game. This season, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that Systane® has partnered with the Toronto Blue Jays as the official eye drop of the team. The partnership aims to help Canadians recognize the signs of dry eye and stay comfortable throughout the game. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407095429/en/Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dr
Wells Fargo upgraded Alcon from Equal Weight to Overweight and set a new price target of $97.00
William Blair initiated coverage of Alcon with a rating of Mkt Perform
Deutsche Bank upgraded Alcon from Hold to Buy
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
First-quarter 2026 sales of $2.7 billion, up 10% on a reported basis, or up 6% constant currency1 (cc), versus first-quarter 2025 First-quarter 2026 diluted EPS of $0.39; core diluted EPS2 of $0.85 Dividend of 0.28 CHF per share approved at AGM Announced new $1.5 billion share repurchase authorization over 3 years Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31, 2026. For the first quarter of 2026, sales were $2.7 billion, up 10% on a reported basis and up 6% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported dilu
Shareholders approve all agenda items presented R. Scott Herren elected as new independent member of the Board 2025 Compensation Report and Report on Non-Financial Matters approved in consultative votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2026 Annual General Meeting ("AGM"). A total of 283,222,421 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 11,328,896.84, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the
Alcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect R. Scott Herren as a new independent Board member. An accomplished financial executive with thirty-
SC 13G - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)